Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. - Wikidata - wikimedia - TriplyDB

Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.

Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.

http://www.wikidata.org/entity/Q34176627

about

Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: effect of glycan modification.Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.Arterial pathology in canine mucopolysaccharidosis-I and response to therapy Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI A review of gene therapy in canine and feline models of lysosomal storage disorders.Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I Long-term nonsense suppression therapy moderates MPS I-H disease progression.Chronic Enzyme Replacement to the Brain of a Late Infantile Neuronal Ceroid Lipofuscinosis Mouse Has Differential Effects on Phenotypes of Disease.Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.Orthopaedic aspects of mucopolysaccharidoses.Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs.Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease.Quantification of glycosaminoglycans in urine by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry.Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease.

P2860

Q28551264-5617CE1F-FC1C-451F-BFEE-93A5AF6A8179 Q34005906-CFD6FCF6-378F-4DF9-BC80-B8662AECEB49 Q34246168-C4927148-AAB5-4E74-B6C6-E26902D74884 Q34336466-4378EABF-9E95-44FF-A2F7-A79BD66D1EF0 Q34633305-7FA6AB8F-48C4-443F-9EBF-92BA641D8BD0 Q34883690-C41D0639-ECE7-4CF6-905F-E94677937EE5 Q35088780-23473E1D-4322-4787-87D4-080F4F73A5DB Q35108104-015623D6-1B29-4A47-A98D-59F200752204 Q35600310-158A156D-191E-419D-86BC-C02EF828D114 Q35627722-78AD4004-F5EC-4641-AD64-9DE6A1C3ADF8 Q35894676-9EA5E57C-ACAF-423E-B983-E9C2BB8BAA5E Q36067812-0E9CB98D-8A50-4C03-B39B-00FBB6638DA0 Q36762013-7AF94209-98C8-43E8-9FC3-6C2690A1227B Q37619694-CF72D909-0806-4861-A99F-8598847A132D Q37717896-6E1741F3-1D61-4F8D-8647-F047DF98BF1F Q37726532-F4E9790B-2F94-4F77-AB40-A84DEACB4DC4 Q37972587-6F5CE927-7835-4505-A08B-3596DA64315E Q38853824-FF3A3904-0E8D-4B0B-9136-CE45433CEED1 Q40663776-6135EC1C-19C3-43F6-A6C2-4A7132BCA75D Q41273646-6DD28013-F1CB-4976-AFAD-3058591FC473 Q42177668-1259AFD1-B2E0-4E85-B8B0-5AFD785AC132 Q44758557-C69B841A-F63E-47F6-9497-479EDF645C7A Q48633842-D6EB300F-41F9-4632-BD31-8143C520D1FF

P2860

Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I.

http://www.wikidata.org/entity/Q34176627

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Early versus late treatment of ...... mucopolysaccharidosis type I.

@ast

Early versus late treatment of ...... mucopolysaccharidosis type I.

@en

Early versus late treatment of ...... mucopolysaccharidosis type I.

@nl

type

label

Early versus late treatment of ...... mucopolysaccharidosis type I.

@ast

Early versus late treatment of ...... mucopolysaccharidosis type I.

@en

Early versus late treatment of ...... mucopolysaccharidosis type I.

@nl

prefLabel

Early versus late treatment of ...... mucopolysaccharidosis type I.

@ast

Early versus late treatment of ...... mucopolysaccharidosis type I.

@en

Early versus late treatment of ...... mucopolysaccharidosis type I.

@nl

P1433

Q34176627-B8A5905E-8B5D-4E7A-B00B-3DFEE412B5E8

P1476

Q34176627-F45FAABE-4010-46B8-BB29-C83756B761CC

P2093

Q34176627-03BEFDB9-368A-49B1-AA70-8CFB393F0E5E

Q34176627-0B2581F8-9B50-4DB2-8410-41A06AAE58AC

Q34176627-0FDBA73D-67E7-4D6E-99C4-9DA7E92BB127

Q34176627-12C753CA-08A1-4408-9EDB-57AEAB6FC802

Q34176627-398BBC7D-AA76-43B8-8548-8D5D70CFFEB5

Q34176627-40D71AEF-137E-4FCD-8BEA-4E1DEAF2DAA8

Q34176627-69DB3916-574A-454B-92E2-B57D5B676777

Q34176627-7516435A-E8E4-4E12-8B5F-3F10B5D2E2CD

Q34176627-A7C34E8A-4E49-449F-A28A-1DCD674EC17B

Q34176627-ACD9545D-6EA8-4F11-ACF3-8FEA35D44EFC

P2860

Q34176627-1ACF505B-2291-4723-92AE-71F83A169508

Q34176627-4D64BA44-B26C-4743-9B85-8738508C6516

Q34176627-56735E14-7405-4DDC-87C4-1BB01C8D030A

Q34176627-683870C7-0435-4FA5-9735-5F8AAD1AEDC5

Q34176627-752BD4EA-716A-4180-8794-B92B131F9063

Q34176627-7B1B33E5-1895-4339-874F-CD70F4DD356A

Q34176627-8079A15F-491E-4859-A235-482F0FD0EB26

Q34176627-86D27DDB-A567-44A3-8154-380E61740236

Q34176627-9BF73529-54FF-4579-A775-9BBA10393893

Q34176627-CA5D913E-A513-4838-8167-50DE726D0794

P304

Q34176627-E8816607-A872-4583-A055-DEC67CC3170B

P31

Q34176627-8A9AABE2-1CF7-4B3F-B4C2-0B113C8B6684

P356

Q34176627-B0DCA73E-8A05-41D3-972C-B739DD14C94F

P433

Q34176627-914F3886-E64C-4B93-A799-CC8F06619035

P478

Q34176627-94503A55-E89B-46B0-AB39-457E7FEAEE5C

P50

Q34176627-8CBAB211-171A-473B-82D9-C06726C8A4F1

Q34176627-9DAD67C3-CB46-4C1B-A52B-C741766D47EF

P577

Q34176627-A792E74F-0568-45D9-A587-A6399680F0D0

P5875

Q34176627-9A45E4B7-8738-4BCF-9A29-453ED9A25C0F

P698

Q34176627-2CBA4E38-ADBA-413D-A120-A9E38AFC3348

P921

Q34176627-B8D25C36-6ED4-4728-A2B7-0AFA6EBEED09

P932

Q34176627-54FD2493-1DD4-49F4-97A0-C0B44ADEA9E6

P356

J.YMGME.2010.06.020

P1433

Molecular Genetics and Metabolism

P1476

Early versus late treatment of ...... e mucopolysaccharidosis type I

@en

P2093

Agnes H Chen

http://www.w3.org/2001/XMLSchema#string

Anton Mlikotic

http://www.w3.org/2001/XMLSchema#string

Ashley Dierenfeld

http://www.w3.org/2001/XMLSchema#string

Brigette L Tippin

http://www.w3.org/2001/XMLSchema#string

Carole A Vogler

http://www.w3.org/2001/XMLSchema#string

Catalina Guerra

http://www.w3.org/2001/XMLSchema#string

Charles H Vite

http://www.w3.org/2001/XMLSchema#string

Jackie Jens

http://www.w3.org/2001/XMLSchema#string

Katherine P Ponder

http://www.w3.org/2001/XMLSchema#string

Mark E Haskins

http://www.w3.org/2001/XMLSchema#string

P2860

Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid

Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.

Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I

Mucopolysaccharidoses and spinal cord compression: case report and review of the literature with implications of bone marrow transplantation.

Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I

Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature.

Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.

Myelographic features of mucopolysaccharidoses: a new sign.

Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I.

Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

P304

115-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YMGME.2010.06.020

http://www.w3.org/2001/XMLSchema#string

P433

2-3

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Michael F. McEntee

P577

2010-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45286717

http://www.w3.org/2001/XMLSchema#string

P698

20655780

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

2950221

http://www.w3.org/2001/XMLSchema#string